Table 3.

Complete comparison of clinical and imaging data in patients with and without disease progression

Baseline characteristics (n = 86)	No progression (n = 54)	Progression (n = 32)	P value
Age (years), mean ± SD	54.46 ± 17.33	55.40 ± 22.54	0.306
Sex (male)	30 (57.7%)	22 (42.3%)	0.163
Comorbidities
Diabetes	22 (75.9%)	7 (24.1%)	0.059
COPD	1 (33.3%)	2 (66.7%)	0.285
Smoking	4 (80%)	1 (20%)	0.404
Hyperlipidemia	8 (88.9%)	1 (11.1%)	0.084
CVA	2 (66.7%)	1 (33.3%)	0.888
Cancer	1 (20%)	4 (80%)	0.062
Coronary artery disease	13 (61.9%)	8 (38.1%)	0.560
Heart failure	1 (100%)	0 (0%)	0.441
CKD	4 (50%)	4 (50%)	0.337
Hypertension	20 (55.6%)	16 (44.4%)	0.171

Echocardiographic data (n = 86)	No progression (n = 54)	Progression (n = 32)	P value
LVEF (%), mean ± SD	52.31 ± 1.11	45.50 ± 5.26	0.160
Normal/Mild LV systolic dysfunction	42 (59.2%)	29 (40.8%)
Moderate LV systolic dysfunction	8 (80%)	2 (20%)
Severe LV systolic dysfunction	4 (80%)	1 (20%)
LV diastolic dysfunction	31 (55.4%)	25 (44.6%)	0.052
sPAP (mmHg), mean ± SD	26.23 ± 3.91	34.00 ± 8.21	0.002
Pericardial effusion
None	53 (65.4%)	28 (34.6%)	0.034
Minimal	1 (33.3%)	2 (66.7%)
Mild	0 (0%)	1 (100%)
Moderate	0 (0%)	1 (100%)
TAPSE	22.17 ± 3.81	19.53 ± 3.90	0.005

Chest CT findings (n = 50)	No progression (n = 30)	Progression (n = 20)	P value
Total CT score	9.06 ± 3.73	6.39 ± 2.72	0.002
Distribution			0.791
Left sided	1 (50%)	1 (50%)
Right sided	2 (100%)	0 (0%)
Bilateral	27 (58.7%)	19 (41.3%)
Pattern
GGO	16 (59.3%)	11 (40.7%)	0.569
Consolidation	14 (60.9%)	9 (39.1%)
Result
Intermediate	3 (50%)	3 (50%)	0.598
Highly suggestive	27 (61.4%)	17 (38.6%)

CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CVA cerebrovascular accident, GGO ground glass opacification, LVEF left ventricular ejection fraction, sPAP systolic pulmonary artery pressure, TAPSE tricuspid annular systolic plane excursion